Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Multiple Myeloma 24Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Smoldering Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Plasma Cell 2Brain Neoplasms 2Blast Crisis 2Renal Insufficiency 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Accelerated Phase 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Dyspnea 1Down Syndrome 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 117Cyclophosphamide 104fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Cytarabine 47Etoposide 44Mycophenolic Acid 41Filgrastim 40Whole-Body Irradiation 37Tacrolimus 36Melphalan 35Bortezomib 34Methotrexate 33Cyclosporine 33Busulfan 31Radiotherapy 30Vincristine 28Doxorubicin 27Dexamethasone 27Carmustine 25Antilymphocyte Serum 25Lenalidomide 23Bendamustine Hydrochloride 23ibrutinib 22Granulocyte Colony-Stimulating Factor 20obinutuzumab 18fludarabine 18acalabrutinib 18Prednisone 18venetoclax 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Mantle-Cell × auricularum × Clear all
NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
131 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
51 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT01527149 2024-02-07

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Roswell Park Cancer Institute

Phase 2 Completed
37 enrolled 19 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT03232307 2019-08-22

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡